These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803 [TBL] [Abstract][Full Text] [Related]
24. In vitro susceptibility-testing in Aspergillus species. Lass-Flörl C; Perkhofer S Mycoses; 2008 Sep; 51(5):437-46. PubMed ID: 18422914 [TBL] [Abstract][Full Text] [Related]
25. Current status of antifungal susceptibility testing methods. Arikan S Med Mycol; 2007 Nov; 45(7):569-87. PubMed ID: 17885947 [TBL] [Abstract][Full Text] [Related]
26. Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey. Oz Y; Qoraan I; Oz A; Balta I Int J Dermatol; 2017 Jan; 56(1):68-74. PubMed ID: 27667305 [TBL] [Abstract][Full Text] [Related]
27. Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. Ghannoum MA; Chaturvedi V; Espinel-Ingroff A; Pfaller MA; Rinaldi MG; Lee-Yang W; Warnock DW J Clin Microbiol; 2004 Jul; 42(7):2977-9. PubMed ID: 15243047 [TBL] [Abstract][Full Text] [Related]
28. Testing of antifungal combinations against yeasts and dermatophytes. Harman S; Ashbee HR; Evans EG J Dermatolog Treat; 2004 Apr; 15(2):104-7. PubMed ID: 15204161 [TBL] [Abstract][Full Text] [Related]
29. Comparison between the standardized clinical and laboratory standards institute M38-A2 method and a 2,3-Bis(2-Methoxy-4-Nitro-5-[(Sulphenylamino)Carbonyl]-2H-tetrazolium hydroxide- based method for testing antifungal susceptibility of dermatophytes. Shehata AS; Mukherjee PK; Ghannoum MA J Clin Microbiol; 2008 Nov; 46(11):3668-71. PubMed ID: 18832129 [TBL] [Abstract][Full Text] [Related]
30. Molecular characterization and antifungal activity against non-dermatophyte molds causing onychomycosis. Pakshir K; Kamali M; Nouraei H; Zomorodian K; Motamedi M; Mahmoodi M Sci Rep; 2021 Oct; 11(1):20736. PubMed ID: 34671053 [TBL] [Abstract][Full Text] [Related]
31. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. Hazen KC J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S37-41. PubMed ID: 9594935 [TBL] [Abstract][Full Text] [Related]
32. Drug Sensitivity Profile of Fungi Isolated from Onychomycosis Patients and Evaluation of Squalene Epoxidase Mutation in One Terbinafine-Resistant Firooz A; Daneshpazhooh M; Lotfali E; Sharzad Kavkani M; Ghasemi Z; Khamesipoor A; Nassiri Kashani M; Miramin Mohammadi A; Skandari SE; Ahmad Nasrollahi S; Fattahi A Microb Drug Resist; 2021 Dec; 27(12):1658-1663. PubMed ID: 34297623 [No Abstract] [Full Text] [Related]
34. Susceptibility testing of terbinafine alone and in combination with amphotericin B, itraconazole, or voriconazole against conidia and hyphae of dematiaceous molds. Biancalana FS; Lyra L; Moretti ML; Schreiber AZ Diagn Microbiol Infect Dis; 2011 Dec; 71(4):378-85. PubMed ID: 21945391 [TBL] [Abstract][Full Text] [Related]
35. Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates. Salehi Z; Shams-Ghahfarokhi M; Razzaghi-Abyaneh M Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1841-1846. PubMed ID: 29980898 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). Barros MEDS; Santos DA; Hamdan JS J Med Microbiol; 2007 Apr; 56(Pt 4):514-518. PubMed ID: 17374893 [TBL] [Abstract][Full Text] [Related]
37. In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes. Ghannoum M; Isham N; Long L Antimicrob Agents Chemother; 2015 Sep; 59(9):5154-8. PubMed ID: 26055386 [TBL] [Abstract][Full Text] [Related]
38. In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China. Li RY; Wan Z; Wang AP; Shen YN; Lu CM; Li M; Xi LY; Liu WD; Zeng FQ Mycoses; 2004 Oct; 47(9-10):402-6. PubMed ID: 15504124 [TBL] [Abstract][Full Text] [Related]
39. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Arendrup MC; Meletiadis J; Mouton JW; Guinea J; Cuenca-Estrella M; Lagrou K; Howard SJ; Clin Microbiol Infect; 2016 Jun; 22(6):571.e1-4. PubMed ID: 26851656 [TBL] [Abstract][Full Text] [Related]